NO. 021 · STAGE 2 · Lv. 86 · HP 190
MAZDUTIDE
GLP-1 + Glucagon · Innovent
ALIASES
Mazdutide, IBI362, LY3305677
CLASS
GLP-1/glucagon dual receptor agonist (Innovent/Lilly)
FORMULA
Synthetic peptide · oxyntomodulin-derived
HALF-LIFE
~7 days (once-weekly)
ROUTES
Subcutaneous (Phase 3 clinical)
MECHANISM OF ACTION
Innovent Biologics dual GLP-1 and glucagon receptor agonist (IBI362), derived from oxyntomodulin lineage. Approved in China 2024 for chronic weight management. Phase 3 GLORY program ongoing.
EVIDENCE GRADES
Zhao 2024 JAMA Netw Open · placebo-subtracted weight loss ~11.1% at 9 mg/wk over 24 weeks in Chinese adults.
HbA1c reduction in Chinese T2D Phase 2.
48-week Phase 3 obesity met primary endpoint; China NMPA review 2024-2025.
MECHANISM CATEGORIES
SAFETY
Side effects
- GI: nausea, vomiting, diarrhea
- Injection-site reactions
Known interactions
- Class effect · sulfonylureas/insulin
Contraindications
- History of MTC or MEN2
REGULATORY STATUS
FDA · Investigational outside China. Not FDA-approved.
WADA · Not currently listed on the WADA Prohibited List.
STORAGE
Lyophilized · -20 °C 24 months
Reconstituted · 2-8 °C, 28 days
PEER-REVIEWED EVIDENCE
- Zhao H, et al.. Mazdutide IBI362 in obese Chinese adults: dose-finding phase 2. JAMA Netw Open 2024. link →
- Innovent Biologics / Eli Lilly. A phase 3 study of mazdutide in Chinese participants with overweight or obesity (GLORY-1). ClinicalTrials.gov · Phase 3 2024. NCT05216575. link →
FAQ · 6 QUESTIONS
▶ What is mazdutide?
Mazdutide (IBI362) is a once-weekly synthetic peptide GLP-1/glucagon dual agonist developed by Innovent Biologics under license from Eli Lilly. It is in late-stage clinical development in China for type 2 diabetes and obesity.
▶ How is mazdutide different from survodutide?
Both are GLP-1/glucagon dual agonists. Mazdutide is developed primarily for the Chinese market by Innovent under license from Lilly; survodutide is Boehringer Ingelheim/Zealand's molecule for the global market. Different sequence, similar mechanism.
▶ What weight loss has Phase 2 shown?
24-week Phase 2 in Chinese adults (Zhao 2024) reported placebo-subtracted weight loss ~11.1% at the 9 mg/wk dose.
▶ Is mazdutide approved?
China NMPA review ongoing for obesity (as of 2026-05). Not FDA-approved.
▶ Dose in trials?
Phase 2/3 trials titrated subcutaneous 3-9 mg once weekly. This wiki does not recommend any human dose.
▶ How does it work?
Dual agonism at the GLP-1 and glucagon receptors. GLP-1 arm drives satiety + glucose-dependent insulin secretion; glucagon arm drives hepatic lipolysis + energy expenditure.
SIGNATURE MOVES
Both receptors fire. Oxyntomodulin lineage.
China approval 2024. Phase 3 GLORY program.
SOURCED FROM PEPPU LABS
Reference compounds documented on this page are available as research-grade material at Peppu Studio · ≥99% purity · per-batch Certificate of Analysis. For laboratory research use only. No human dose is recommended by this wiki.
▶ LAST UPDATED · 2026-05-19